Omniscient closes US$27.2M Series D for AI brain-mapping platform
What's the deal? OmniscientDealroom has a profile for this one. Try Dealroom →, which builds AI-driven brain analysis technology, has closed an oversubscribed $27.2M Series D round. The funding is co-led by OIF VenturesDealroom has a profile for this one. Try Dealroom → and the Australian National Reconstruction FundDealroom has a profile for this one. Try Dealroom → Corporation (NRFC), with continued backing from long-term investors including Will VicarsDealroom has a profile for this one. Try Dealroom → and Gina RinehartDealroom has a profile for this one. Try Dealroom →.
The San Francisco-based company makes Quicktome, an FDA-cleared platform that uses AI and connectomics to map individual brains — visualising functional regions and neural pathways responsible for language, movement, and cognition. Clinicians use these maps to avoid neurological complications during procedures and improve patient outcomes.
The capital will fund two priorities: scaling sales and clinical support staff to serve a growing base of US healthcare networks, and developing next-generation brain AI tools for new markets like brain computer interfaces (BCI), stroke, and movement disorders.
Why now? The round follows a key reimbursement milestone — a new CPT code (1039T) that establishes a billing pathway for connectomic analysis across the US healthcare system. That code makes it significantly easier for hospitals to adopt and pay for the technology, creating a commercial inflection point.
"AI lets us turn the vast complexity of the human brain into clear, actionable intelligence," said Stephen Scheeler, chief executive officer of Omniscient. "This funding scales that capability, bringing AI-driven precision brain medicine to patients, physicians, and partners in the US and worldwide."
What could go wrong? Medical AI faces a long road from reimbursement codes to widespread adoption. Hospitals are notoriously slow to integrate new technologies, and Omniscient will need to prove clinical value at scale to justify ongoing use. The company also faces the challenge of expanding into adjacent markets — stroke, Alzheimer's, Parkinson's, depression — where the science is less established and regulatory hurdles may differ.
The signal: The investor mix here is telling — a government-backed reconstruction fund (NRFC), a venture fund in OIF Ventures, and high-profile angel investors like Gina Rinehart and Will Vicars all converging on a still-early-growth company suggests deep conviction in connectomics as a category, not just a niche surgical tool. The new CPT billing code removes one of medtech's biggest adoption barriers, and with Omniscient now pushing into BCI, stroke, and movement disorders, the bet is that brain mapping follows the trajectory of genomics: from specialist use case to platform infrastructure.
Read more: benzinga.com
